Skin vaccination against cervical cancer associated human papillomavirus with a novel micro-projection array in a mouse model

PLoS ONE

Volumn 5, Issue 10, 2010, Pages

  Corbett, Holly J ^a   Fernando, Germain J P ^a   Chen, Xianfeng ^a   Frazer, Ian H ^a   Kendall, Mark A F ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE; HUMAN PAPILLOMAVIRUS VACCINE L1, TYPE 6,11,16,18;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CANCER IMMUNIZATION; CANCER PREVENTION; CONTROLLED STUDY; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG RELEASE; FEMALE; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNE RESPONSE; MOUSE; NANOPHARMACEUTICS; NONHUMAN; SKIN PENETRATION; TRANSDERMAL PATCH; TUMOR IMMUNITY; UTERINE CERVIX CANCER; VIRUS NEUTRALIZATION; ALPHAPAPILLOMAVIRUS; ANIMAL; C57BL MOUSE; DOSE RESPONSE; IMMUNOLOGY; SCANNING ELECTRON MICROSCOPY; SKIN; UTERINE CERVIX TUMOR;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; MUS;

ALPHAPAPILLOMAVIRUS; ANIMALS; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; MICE; MICE, INBRED C57BL; MICROSCOPY, ELECTRON, SCANNING; MODELS, ANIMAL; PAPILLOMAVIRUS VACCINES; SKIN; UTERINE CERVICAL NEOPLASMS;

EID: 78149417453     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0013460     Document Type: Article

References (53)

1. Prüss-Üstün A, Rapiti E, Hutin Y (2005) Estimation of the global burden of disease attributable to contaminated sharps injuries among health-care workers. Am J Ind Med 48: 482-490.
2. Miller MA, Pisani E (1999) The cost of unsafe injections. Bull World Health Organ 77: 808-811.
3. Simonsen L, Kane A, Lloyd J, Zaffran M, Kane M (1999) Unsafe injections in the developing world and transmission of bloodborne pathogens: a review. Bull World Health Organ 77: 789-800.
4. Hamilton JG (1995) Needle phobia: a neglected diagnosis. J Fam Pract 41: 169-175.
5. Nir Y, Paz A, Sabo E, Potasman I (2003) Fear of injections in young adults: prevalence and associations. Am J Trop Med Hyg 68: 341-344.
6. Schuler G, Steinman RM (1985) Murine epidermal Langerhans cells mature into potent immunostimulatory dendritic cells in vitro. J Exp Med 161: 526-546.
7. López-Bravo M, Ardavín C (2008) In Vivo Induction of Immune Responses to Pathogens by Conventional Dendritic Cells. Immunity 29: 343-351.
8. Kendall M (2006) Engineering of needle-free physical methods to target epidermal cells for DNA vaccination. Vaccine 24: 4651-4656.
9. Mitragotri S (2005) Immunization without needles. Nat Rev Immunol 5: 905-916.
10. Fernando GJP, Chen X, Prow TW, Crichton ML, Fairmaid EJ, et al. (2010) Potent Immunity to Low Doses of Influenza Vaccine by Probabilistic Guided Micro-Targeted Skin Delivery in a Mouse Model. PLoS ONE 5: e10266.
11. Crichton ML, Ansaldo A, Chen X, Prow TW, Fernando GJP, et al. (2010) The effect of strain rate on the precision of penetration of shortly densely-packed microprojection array patches coated with vaccine. Biomaterials;doi:10.1016/j.biomaterials.2010.02.022.
12. Gupta RK (1998) Aluminum compounds as vaccine adjuvants. Adv Drug Deliver Rev 32: 155-172.
13. Baylor NW, Egan W, Richman P (2002) Aluminum salts in vaccines-US perspective. Vaccine 20: S18-S23.
14. Kundi M (2007) New hepatitis B vaccine formulated with an improved adjuvant system. Expert Rev Vaccines 6: 133-140.
15. Osorio JE, Zuleger CL, Burger M, Chu QL, Payne LG, et al. (2003) Immune responses to hepatitis B surface antigen following epidermal powder immunization. Immunol Cell Biol 81: 52-58.
16. Maa YF, Shu C, Ameri M, Zuleger C, Che J, et al. (2003) Optimization of an alum-adsorbed vaccine powder formulation for epidermal powder immunization. Pharm Res 20: 969-977.
17. Maa Y-F, Zhao L, GPayne L, Chen D (2003) Stabilization of alum-adjuvanted vaccine dry powder formulations: Mechanism and application. J Pharm Sci 92: 319-332.
18. Mizuno K, Ishihara Y, Kawahara T, Ohtomo N (1989) Hepatitis B vaccine and method for its preparation. European Patent # 0130619.
19. Shinje G, Neil DC, John WK, Jenson AB (1991) Comparison of neutralization of BPV-1 infection of C127 cells and bovine fetal skin xenografts. Int J Cancer 49: 285-289.
20. Jan MMW, Marcel VJ, Manos MM, Bosch FX, Kummer JA, et al. (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189: 12-19.
21. Zhou J, Sun XY, Stenzel DJ, Frazer IH (1991) Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology 185: 251-257.
22. Kirnbauer R, Taub J, Greenstone H, Roden R, Durst M, et al. (1993) Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J Virol 67: 6929-6936.
23. Werness BA, Levine AJ, Howley PM (1990) Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 248: 76-79.
24. Phelps WC, Yee CL, Münger K, Howley PM (1988) The human papillomavirus type 16 E7 gene encodes transactivation and transformation functions similar to those of adenovirus E1A. Cell 53: 539-547.
25. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM (1990) The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63: 1129-1136.
26. Group TFIS (2007) Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 356: 1915-1927.
27. Lowy DR, Schiller JT (2006) Prophylactic human papillomavirus vaccines. J Clin Invest 116: 1167-1173.
28. Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow SN, et al. (2009) Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. The Lancet 374: 301-314.
29. Hillard W, Stuart B, Willard C, Jr. (2004) Sexually Transmitted Diseases Among American Youth: Incidence and Prevalence Estimates, 2000. Perspect Sex Repro H 36: 6-10.
30. Winer RL, Lee S-K, Hughes JP, Adam DE, Kiviat NB, et al. (2003) Genital Human Papillomavirus Infection: Incidence and Risk Factors in a Cohort of Female University Students. Am J Epidemiol 157: 218-226.
31. O'Connor K (2007) Herd immunity. Aust Fam Physician 36: 677.
32. Dunne EF, Unger ER, Sternberg M, McQuillan G, Swan DC, et al. (2007) Prevalence of HPV Infection Among Females in the United States. JAMA 297: 813-819.
33. Yuan H, Estes PA, Chen Y, Newsome J, Olcese VA, et al. (2001) Immunization with a Pentameric L1 Fusion Protein Protects against Papillomavirus Infection. J Virol 75: 7848-7853.
34. Suzich JA, Ghim SJ, Palmer-Hill FJ, White WI, Tamura JK, et al. (1995) Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. P Natl Acad Sci USA 92: 11553-11557.
35. Finch JT, Klug A (1965) The structure of viruses of the papilloma-polyoma type: III. Structure of rabbit papilloma virus with an appendix on the topography of contrast in negative-staining for electron-microscopy. J Mol Biol 13: 1-12, IN11-IN17.
36. Baker TS, Newcomb WW, Olson NH, Cowsert LM, Olson C, et al. (1991) Structures of bovine and human papillomaviruses. Analysis by cryoelectron microscopy and three-dimensional image reconstruction. Biophys J 60: 1445-1456.
37. McCarthy MP, White WI, Palmer-Hill F, Koenig S, Suzich JA (1998) Quantitative Disassembly and Reassembly of Human Papillomavirus Type 11 Viruslike Particles In Vitro. J Virol 72: 32-41.
38. Lenz P, Day PM, Pang Y-YS, Frye SA, Jensen PN, et al. (2001) Papillomavirus-Like Particles Induce Acute Activation of Dendritic Cells. J Immunol 166: 5346-5355.
39. Thones N, Herreiner A, Schadlich L, Piuko K, Muller M (2008) A Direct Comparison of Human Papillomavirus Type 16 L1 Particles Reveals a Lower Immunogenicity of Capsomeres than Viruslike Particles with Respect to the Induced Antibody Response. J Virol 82: 5472-5485.
40. Shank-Retzlaff ML, Zhao Q, Anderson C, Hamm M, High K, et al. (2006) Evaluation of the thermal stability of Gardasil. Hum Vaccin 2: 147-154.
41. Le Tallec D, Doucet D, Elouahabi A, Harvengt P, Deschuyteneer M, et al. (2009) Cervarix, the GSK HPV-16/HPV-18 AS04-adjuvanted cervical cancer vaccine, demonstrates stability upon long-term storage and under simulated cold chain break conditions. Hum Vaccin 5: 467-474.
42. Chen X, Prow TW, Crichton ML, Jenkins DWK, Roberts MS, et al. (2009) Drycoated microprojection array patches for targeted delivery of immunotherapeutics to the skin. J Control Release 139: 212-220.
43. Einstein MH, Baron M, Levin MJ, Chatterjee A, Edwards RP, et al. (2009) Comparison of the immunogenicity and safety of Cervarix() and Gardasil((R)) human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum Vaccin 5: 705-719.
44. Nokleby H (2006) Vaccination and anaphylaxis. Curr Allergy Asthm R 6: 9-13.
45. World Health Organization Expert Committee on Biological Standardization (2006) Guidelines to assure the quality, safety and efficacy of recombinant human papillomavirus virus-like particle vaccines. Geneva: WHO.
46. World Health Organization (2008) WHO meeting on the standardization of HPV assays and the role of WHO HPV LabNet in supporting vaccine introduction. Geneva: WHO.
47. Buck CB, Pastrana DV, Lowy DR, Schiller JT (2006) Generation of HPV Pseudovirions Using Transfection and Their Use in Neutralization Assays. Human Papillomaviruses. pp 445-462.
48. Ghim S-j, Newsome J, Bell J, Sundberg JP, Schlegel R, et al. (2000) Spontaneously Regressing Oral Papillomas Induce Systemic Antibodies That Neutralize Canine Oral Papillomavirus. Exp Mol Pathol 68: 147-151.
49. Breitburd F, Kirnbauer R, Hubbert NL, Nonnenmacher B, Trin-Dinh-Desmarquet C, et al. (1995) Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol 69: 3959-3963.
50. Kenney RT, Frech SA, Muenz LR, Villar CP, Glenn GM (2004) Dose Sparing with Intradermal Injection of Influenza Vaccine. N Engl J Med 351: 2295-2301.
51. Kendall MAF (2005) Device for Delivery of Bioactive Materials and Other Stimuli. In: WIPO Patent WO 2005/072630, editor.
52. Pastrana DV, Buck CB, Pang Y-YS, Thompson CD, Castle PE, et al. (2004) Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology 321: 205-216.
53. Fieller EC (1940) The Biological Standardization of Insulin. Supp J R Stat Soc 7: 1-64.